Leerink Swann reissued their market perform rating on shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) in a research note released on Tuesday, January 2nd, Marketbeat reports. Leerink Swann currently has a $15.00 price target on the biopharmaceutical company’s stock. Leerink Swann also issued estimates for Sucampo Pharmaceuticals’ FY2019 earnings at $1.79 EPS, FY2020 earnings at $2.02 EPS and FY2021 earnings at $2.19 EPS.
A number of other research analysts also recently issued reports on SCMP. Maxim Group restated a buy rating and set a $23.00 price target on shares of Sucampo Pharmaceuticals in a research note on Thursday, November 2nd. Mizuho downgraded Sucampo Pharmaceuticals from a buy rating to a neutral rating and dropped their price target for the stock from $14.00 to $12.00 in a research note on Tuesday, October 3rd. B. Riley raised their price target on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the stock a buy rating in a research note on Wednesday, December 6th. Instinet started coverage on Sucampo Pharmaceuticals in a research note on Tuesday, December 19th. They issued a buy rating and a $43.00 target price on the stock. Finally, ValuEngine upgraded Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Sunday, December 31st. Six research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of Buy and an average price target of $21.58.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at $18.05 on Tuesday. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. Sucampo Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $18.75. The stock has a market capitalization of $867.89, a PE ratio of 12.60, a price-to-earnings-growth ratio of 5.17 and a beta of 1.45.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The business had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. During the same quarter last year, the company earned $0.30 EPS. The business’s quarterly revenue was up 5.9% on a year-over-year basis. equities research analysts expect that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.
In related news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares of the company’s stock, valued at $858,379.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 4.13% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in SCMP. Point72 Asset Management L.P. acquired a new position in shares of Sucampo Pharmaceuticals in the third quarter worth $21,989,000. Prudential Financial Inc. raised its holdings in shares of Sucampo Pharmaceuticals by 871.6% in the third quarter. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company’s stock worth $4,842,000 after acquiring an additional 368,090 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Sucampo Pharmaceuticals by 13.0% in the second quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock worth $17,287,000 after acquiring an additional 189,561 shares during the last quarter. Systematic Financial Management LP acquired a new position in shares of Sucampo Pharmaceuticals in the second quarter worth $1,648,000. Finally, Royce & Associates LP raised its holdings in shares of Sucampo Pharmaceuticals by 9.7% in the third quarter. Royce & Associates LP now owns 1,171,731 shares of the biopharmaceutical company’s stock worth $13,826,000 after acquiring an additional 103,808 shares during the last quarter. 65.29% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/sucampo-pharmaceuticals-scmp-stock-rating-reaffirmed-by-leerink-swann.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.